MiMedx Group, Inc. 2023 Form 10-K Summary
Business context and reporting period
MiMedx develops and sells human placental tissue allografts for wound care, burn, and surgical applications, primarily in the United States, with an emerging presence in Japan. Key products include EPIFIX, EPICORD, EPIEFFECT, AMNIOFIX, AMNIOCORD, AMNIOEFFECT, and AXIOFILL. The filing covers the fiscal year ended December 31, 2023; fourth-quarter information is also disclosed.
Management disbanded the Regenerative Medicine business unit and suspended the knee osteoarthritis clinical trial program in 2023. That activity is presented as discontinued operations, leaving Wound & Surgical as the Company’s continuing reportable business.
Financial performance and liquidity
| Metric | 2023 | 2022 | Change |
|---|---|---|---|
| Full-year net sales | $321.5 million | $267.8 million | Up 20.0% |
| Fourth-quarter net sales | $86.8 million | Not clearly provided in the filing text | Up 16.7% |
| Gross profit | $266.8 million | $219.5 million | Up 21.6% |
| Gross margin | 83.0% | 82.0% | Up 100 basis points |
| Operating income | $37.1 million | $(14.7) million | Improved |
| Net income from continuing operations | $67.4 million | $(20.0) million | Improved |
| Net income | $58.2 million | $(30.2) million | Improved |
| Diluted earnings per share | $0.37 | $(0.33) | Improved |
| Cash flow from continuing operations | $34.9 million provided | $8.0 million used | Improved by $42.9 million |
Hospital sales increased 14.6% to $187.0 million, private-office sales increased 24.1% to $95.8 million, and other-site sales increased 40.8% to $38.7 million. The filing attributes growth to commercial execution, demand, newer products, and initial contributions from Japan.
SG&A increased 1.2% to $211.1 million, while research and development expense was essentially unchanged at $12.7 million. Investigation, restatement, and related expense declined 57.5% to $5.2 million. Net interest expense increased to $6.5 million from $5.0 million because of higher reference rates.
Cash and cash equivalents were $82.0 million at December 31, 2023, compared with $66.0 million at December 31, 2022. Net working capital was $118.3 million and the current ratio was 3.6 to 1. Accounts receivable were $53.9 million and inventory was $21.0 million.
Reported long-term debt, net, was $48.1 million at year-end, representing the Hayfin term loan. In January 2024, the Company replaced the Hayfin facility with a $95.0 million senior secured credit structure consisting of a $75.0 million revolver and a $20.0 million term loan. It initially drew $30.0 million on the revolver and $20.0 million on the term loan, then repaid the initial $30.0 million revolver draw on February 27, 2024. The facilities mature in January 2029 and contain leverage, fixed-charge coverage, and other restrictive covenants.
Material changes versus the prior comparable period
- Revenue growth accelerated across hospital, private-office, and other care settings.
- Gross margin improved from 82.0% to 83.0%, supported by product mix and manufacturing efficiencies.
- The Company moved from an operating loss to operating income, and continuing operations became profitable.
- Operating cash flow from continuing operations improved from a $8.0 million use of cash to a $34.9 million source of cash.
- The Regenerative Medicine business unit was disbanded and its results were reclassified as discontinued operations. Discontinued operations generated a $9.2 million net loss in 2023, including restructuring and goodwill impairment effects.
- EPIEFFECT was launched in October 2023 and received a Medicare HCPCS code effective July 1, 2023.
- All outstanding Series B preferred stock was converted into 29.8 million common shares in December 2023. The Company also repurchased 5,000 preferred shares for $9.5 million during October 2023.
- The Company changed senior leadership, including appointing a new CEO, CFO, and Chief Operating Officer.
Guidance, outlook, risks, contingencies, and unusual items
The filing does not provide formal revenue or earnings guidance. Management expects to focus on expanding Wound & Surgical, developing adjacent products, increasing international penetration, improving efficiency, and generating a profitable, cash-flow-positive business. Management cites an estimated U.S. wound and surgical market of approximately $2.0 billion and expects that market to grow 7% to 10% annually over the three to five years beginning in 2023; these are market estimates rather than Company guidance.
The most significant regulatory matter is the FDA’s December 21, 2023 Warning Letter concerning AXIOFILL. Following 2023 inspections, the FDA indicated that AXIOFILL appeared to be regulated under Section 351 of the Public Health Service Act rather than solely as a Section 361 HCT/P. The Company is engaging with the FDA to obtain a formal classification determination. A determination requiring premarket approval or clearance could increase costs, delay commercialization, or require suspension of sales.
Other major risks include changes to Medicare and private-payer reimbursement for skin substitutes, dependence on group purchasing organizations and integrated delivery networks, reliance on donated human tissue, competition and pricing pressure, product quality and liability risks, cybersecurity threats, regulatory compliance, and dependence on key personnel. Approximately 79% of 2023 sales came from customers that are members of the Company’s primary GPOs or IDNs, and approximately 24% were made through independent agents.
The effective tax rate was unusually favorable because the Company reversed most of its deferred-tax-asset valuation allowance. The reversal produced a $40.8 million deferred tax benefit, leaving $40.8 million of net deferred tax assets after a $0.9 million valuation allowance. Future tax benefits depend on continued realizability of those assets.
The Company faces litigation, including the Welker v. MiMedx matter and continuing indemnification-related matters involving former executives. No legal accrual was recorded for expected settlement costs at December 31, 2023, but management states that actual resolution costs could exceed recorded amounts. A $3.1 million separation obligation to the former CEO remains payable through September 2024, with $1.2 million accrued at year-end.
Deloitte & Touche LLP issued an unqualified audit opinion on the financial statements and internal control over financial reporting. Revenue recognition for ship-and-bill and consignment arrangements was identified as the critical audit matter.
Important facts for investors to verify
- Confirm the FDA’s final classification and required regulatory pathway for AXIOFILL and assess any effect on sales, inventory, compliance costs, or product availability.
- Monitor Medicare, MAC, and private-payer reimbursement changes for skin substitutes, particularly in the private-office setting.
- Evaluate whether revenue growth and 83.0% gross margins are sustainable after product-mix, reimbursement, and commission effects.
- Review cash conversion, accounts receivable growth, inventory growth, and the Company’s ability to remain cash-flow positive.
- Assess compliance with the Citizens credit facilities’ leverage and fixed-charge coverage covenants and exposure to SOFR-based interest rates.
- Separate continuing-operations profitability from the $36.8 million reported income-tax benefit and the $9.2 million loss from discontinued operations.
- Track the Welker litigation, former-executive indemnification matters, and other potential legal or regulatory liabilities.
- Consider dilution from the 29.8 million preferred-stock conversion and outstanding equity awards.
- Verify dependence on GPOs, IDNs, independent sales agents, donated tissue supply, and key customers or distribution partners.